<DOC>
	<DOCNO>NCT00941343</DOCNO>
	<brief_summary>Primary Objective : - To assess sexual function Benign Prostatic Hyperplasia patient Secondary Objective : - To evaluate association Lower Urinary Tract Symptoms severity sexual disorder - To compare sexual function , urinary symptom Quality Life Benign Prostatic Hyperplasia patient XATRAL 10mg OD among different region - To correlate Male Sexual Health Questionnaire ( MSHQ ) 5-item version International Index Erectile Function ( IIEF-5 ) - To assess onset action XATRAL 10mg OD - To assess peak urinary flow rate - To assess safety tolerability XATRAL 10mg OD</brief_summary>
	<brief_title>Benign Prostatic Hyperplasia Taiwan</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Inclusion criterion Male suffer moderate severe low urinary tract symptom ( LUTS ) , suggestive symptomatic Benign Prostatic Hyperplasia ( BPH ) Sexually active Sexual attempt least per month Exclusion criterion Known history hepatic severe renal insufficiency unstable angina pectoris concomitant threateninglife condition Previous transurethral resection prostate ( TURP ) Had minimally invasive procedure within 6 month prior inclusion Planned prostate surgery minimally invasive procedure whole study period Active urinary tract infection acute prostatitis Neuropathic bladder Diagnosed prostate cancer Patients receive 5reductase inhibitor Lower Urinary Tract Symptoms ( LUTS ) relate phytotherapy antimuscarinics drug OAB 1blockers within 1 month prior inclusion Patients receive treatment erectile dysfunction within 1 month prior inclusion History postural hypotension syncope Known hypersensitivity alfuzosin Patients illiterate unable understand complete questionnaire Patients participate clinical study past month Prostate Specific Antigen ( PSA ) &gt; age specific Prostate Specific Antigen value , without use prostate biopsy rule prostate cancer The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>